Arrowhead Pharmaceuticals Inc. (ARWR) Misses Q3 EPS by 40c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q3 EPS of ($1.26), $0.40 worse than the analyst estimate of ($0.86). Revenue for the quarter came in at $27.77 million versus the consensus estimate of $53.9 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• U.S. and Denmark close in on a Greenland deal - Reuters
• Honeywell wins $53.9M Navy contract for navigation parts
• SmartKem (SMTK) files for 15.13M share offering by selling stockholders